> top > docs > PubMed:23323000 > annotations

PubMed:23323000 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-96 Sentence denotes Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.
T2 97-101 Sentence denotes AIM:
T3 102-273 Sentence denotes To investigate the association between interleukin-28B (IL28B) genotype and response to treatment and hepatic fibrosis in patients with hepatitis C virus (HCV) genotype 4.
T4 274-282 Sentence denotes METHODS:
T5 283-341 Sentence denotes Two hundred and one HCV-genotype 4 patients were included.
T6 342-414 Sentence denotes All patients were treated with Peginterferon alph2a/Ribavirin for 48 wk.
T7 415-519 Sentence denotes End of treatment response (ETR) was defined as loss of detectable serum HCV RNA at the end of treatment.
T8 520-629 Sentence denotes Sustained viral response (SVR) was defined as loss of detectable serum HCV RNA at the end of 24 wk follow up.
T9 630-698 Sentence denotes Genotyping of IL28B rs12979860 was performed using the TaqMan assay.
T10 699-779 Sentence denotes We used logistic regression to estimate the adjusted odds ratio (aOR) and 95%CI.
T11 780-788 Sentence denotes RESULTS:
T12 789-836 Sentence denotes The study included 201 HCV-genotype 4 patients.
T13 837-940 Sentence denotes The majority of patients were men (89.6%), with a median age of 47 years, inter-quartile range (40-51).
T14 941-1000 Sentence denotes Approximately 62.5% of patients had ETR, and 49.6% had SVR.
T15 1001-1189 Sentence denotes Individuals who achieved SVR were more likely to be younger (χ(2) = 4.91, P = 0.027), and less likely to have fibrosis (χ(2) = 15.54, P < 0.0001), or inflammation (χ(2) = 7.58, P = 0.006).
T16 1190-1300 Sentence denotes The genotype distribution of rs12979860 was 36.2%, 49.0% and 14.8% for genotypes CC, CT, and TT, respectively.
T17 1301-1482 Sentence denotes In these participants, rs12979860 genotype distribution did not differ by gender (P = 0.466), pretreatment viral load (P = 0.600), inflammation (P = 0.435), or fibrosis (P = 0.291).
T18 1483-1573 Sentence denotes The frequencies of IL28B rs12979860 genotypes were TT (14.8%), CT (49.0%), and CC (36.2%).
T19 1574-1784 Sentence denotes Compared to rs12979860 genotype TT, aORs (95%CI) for ETR and SVR were: CC genotype, [17.55 (5.34-57.69) and 5.92 (2.09-16.76), respectively]; CT genotype, [5.15 (1.80-14.78) and 2.48 (0.94-6.52), respectively].
T20 1785-1991 Sentence denotes In the current study, the patients who did not achieve ETR or SVR had a lower prevalence of rs12979860 CC (17.4% and 23.3%, respectively) than individuals who had ETR or SVR (47.9% and 47.2%, respectively).
T21 1992-2134 Sentence denotes Individuals with rs12979860 CC genotype had approximately 6 times the odds of SVR compared to individuals with TT genotype (aOR = 5.92; 95%CI:
T22 2135-2147 Sentence denotes 2.09-16.76).
T23 2148-2254 Sentence denotes Similarly, patients with CT genotype had SVR more often than patients with TT genotype (aOR = 2.48; 95%CI:
T24 2255-2266 Sentence denotes 0.94-6.52).
T25 2267-2439 Sentence denotes Carrying at least one copy of the C allele (genotypes CT and CC) had almost 8 times the probability of ETR compared to those with genotype rs12979860 TT (aOR = 7.87; 95%CI:
T26 2440-2560 Sentence denotes 2.84-21.82), and approximately 3 times the odds of SVR compared to those with genotype rs12979860 TT (aOR = 3.46; 95%CI:
T27 2561-2572 Sentence denotes 1.37-8.74).
T28 2573-2675 Sentence denotes In addition, data were consistent with a significant gene-dose relationship (aOR = 4.05/allele; 95%CI:
T29 2676-2687 Sentence denotes 2.27-7.22).
T30 2688-2811 Sentence denotes The association between rs12979860 genotype and SVR was similar among those who achieved and those who did not achieve SVR.
T31 2812-2823 Sentence denotes CONCLUSION:
T32 2824-3009 Sentence denotes In HCV-genotype 4 patients, rs12979860 is a sensitive predictor of viral clearance, independent of viral load, age, gender or fibrosis, with no similar relation to severity of fibrosis.
T1 0-96 Sentence denotes Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis.
T2 97-101 Sentence denotes AIM:
T3 102-273 Sentence denotes To investigate the association between interleukin-28B (IL28B) genotype and response to treatment and hepatic fibrosis in patients with hepatitis C virus (HCV) genotype 4.
T4 274-282 Sentence denotes METHODS:
T5 283-341 Sentence denotes Two hundred and one HCV-genotype 4 patients were included.
T6 342-414 Sentence denotes All patients were treated with Peginterferon alph2a/Ribavirin for 48 wk.
T7 415-519 Sentence denotes End of treatment response (ETR) was defined as loss of detectable serum HCV RNA at the end of treatment.
T8 520-629 Sentence denotes Sustained viral response (SVR) was defined as loss of detectable serum HCV RNA at the end of 24 wk follow up.
T9 630-698 Sentence denotes Genotyping of IL28B rs12979860 was performed using the TaqMan assay.
T10 699-779 Sentence denotes We used logistic regression to estimate the adjusted odds ratio (aOR) and 95%CI.
T11 780-788 Sentence denotes RESULTS:
T12 789-836 Sentence denotes The study included 201 HCV-genotype 4 patients.
T13 837-940 Sentence denotes The majority of patients were men (89.6%), with a median age of 47 years, inter-quartile range (40-51).
T14 941-1000 Sentence denotes Approximately 62.5% of patients had ETR, and 49.6% had SVR.
T15 1001-1189 Sentence denotes Individuals who achieved SVR were more likely to be younger (χ(2) = 4.91, P = 0.027), and less likely to have fibrosis (χ(2) = 15.54, P < 0.0001), or inflammation (χ(2) = 7.58, P = 0.006).
T16 1190-1300 Sentence denotes The genotype distribution of rs12979860 was 36.2%, 49.0% and 14.8% for genotypes CC, CT, and TT, respectively.
T17 1301-1482 Sentence denotes In these participants, rs12979860 genotype distribution did not differ by gender (P = 0.466), pretreatment viral load (P = 0.600), inflammation (P = 0.435), or fibrosis (P = 0.291).
T18 1483-1573 Sentence denotes The frequencies of IL28B rs12979860 genotypes were TT (14.8%), CT (49.0%), and CC (36.2%).
T19 1574-1784 Sentence denotes Compared to rs12979860 genotype TT, aORs (95%CI) for ETR and SVR were: CC genotype, [17.55 (5.34-57.69) and 5.92 (2.09-16.76), respectively]; CT genotype, [5.15 (1.80-14.78) and 2.48 (0.94-6.52), respectively].
T20 1785-1991 Sentence denotes In the current study, the patients who did not achieve ETR or SVR had a lower prevalence of rs12979860 CC (17.4% and 23.3%, respectively) than individuals who had ETR or SVR (47.9% and 47.2%, respectively).
T21 1992-2134 Sentence denotes Individuals with rs12979860 CC genotype had approximately 6 times the odds of SVR compared to individuals with TT genotype (aOR = 5.92; 95%CI:
T22 2135-2147 Sentence denotes 2.09-16.76).
T23 2148-2254 Sentence denotes Similarly, patients with CT genotype had SVR more often than patients with TT genotype (aOR = 2.48; 95%CI:
T24 2255-2266 Sentence denotes 0.94-6.52).
T25 2267-2439 Sentence denotes Carrying at least one copy of the C allele (genotypes CT and CC) had almost 8 times the probability of ETR compared to those with genotype rs12979860 TT (aOR = 7.87; 95%CI:
T26 2440-2560 Sentence denotes 2.84-21.82), and approximately 3 times the odds of SVR compared to those with genotype rs12979860 TT (aOR = 3.46; 95%CI:
T27 2561-2572 Sentence denotes 1.37-8.74).
T28 2573-2675 Sentence denotes In addition, data were consistent with a significant gene-dose relationship (aOR = 4.05/allele; 95%CI:
T29 2676-2687 Sentence denotes 2.27-7.22).
T30 2688-2811 Sentence denotes The association between rs12979860 genotype and SVR was similar among those who achieved and those who did not achieve SVR.
T31 2812-2823 Sentence denotes CONCLUSION:
T32 2824-3009 Sentence denotes In HCV-genotype 4 patients, rs12979860 is a sensitive predictor of viral clearance, independent of viral load, age, gender or fibrosis, with no similar relation to severity of fibrosis.

DisGeNET

Id Subject Object Predicate Lexical cue
T0 141-156 gene:282617 denotes interleukin-28B
T1 204-220 disease:C0239946 denotes hepatic fibrosis
T2 141-156 gene:282617 denotes interleukin-28B
T3 238-249 disease:C0019196 denotes hepatitis C
T4 158-163 gene:282617 denotes IL28B
T5 204-220 disease:C0239946 denotes hepatic fibrosis
T6 158-163 gene:282617 denotes IL28B
T7 238-249 disease:C0019196 denotes hepatitis C
R1 T0 T1 associated_with interleukin-28B,hepatic fibrosis
R2 T2 T3 associated_with interleukin-28B,hepatitis C
R3 T4 T5 associated_with IL28B,hepatic fibrosis
R4 T6 T7 associated_with IL28B,hepatitis C

Allie

Id Subject Object Predicate Lexical cue
SS1_23323000_2_0 141-156 expanded denotes interleukin-28B
SS2_23323000_2_0 158-163 abbr denotes IL28B
SS1_23323000_2_1 238-255 expanded denotes hepatitis C virus
SS2_23323000_2_1 257-260 abbr denotes HCV
SS1_23323000_6_0 415-440 expanded denotes End of treatment response
SS2_23323000_6_0 442-445 abbr denotes ETR
SS1_23323000_7_0 520-544 expanded denotes Sustained viral response
SS2_23323000_7_0 546-549 abbr denotes SVR
SS1_23323000_9_0 743-762 expanded denotes adjusted odds ratio
SS2_23323000_9_0 764-767 abbr denotes aOR
AE1_23323000_2_0 SS1_23323000_2_0 SS2_23323000_2_0 abbreviatedTo interleukin-28B,IL28B
AE1_23323000_2_1 SS1_23323000_2_1 SS2_23323000_2_1 abbreviatedTo hepatitis C virus,HCV
AE1_23323000_6_0 SS1_23323000_6_0 SS2_23323000_6_0 abbreviatedTo End of treatment response,ETR
AE1_23323000_7_0 SS1_23323000_7_0 SS2_23323000_7_0 abbreviatedTo Sustained viral response,SVR
AE1_23323000_9_0 SS1_23323000_9_0 SS2_23323000_9_0 abbreviatedTo adjusted odds ratio,aOR

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 204-220 HP_0001395 denotes hepatic fibrosis

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
23323000-1#39#54#gene282617 141-156 gene282617 denotes interleukin-28B
23323000-1#56#61#gene282617 158-163 gene282617 denotes IL28B
23323000-1#102#118#diseaseC0239946 204-220 diseaseC0239946 denotes hepatic fibrosis
23323000-1#136#147#diseaseC0019196 238-249 diseaseC0019196 denotes hepatitis C
23323000-1#102#118#diseaseC0239946 204-220 diseaseC0239946 denotes hepatic fibrosis
23323000-1#136#147#diseaseC0019196 238-249 diseaseC0019196 denotes hepatitis C
39#54#gene282617102#118#diseaseC0239946 23323000-1#39#54#gene282617 23323000-1#102#118#diseaseC0239946 associated_with interleukin-28B,hepatic fibrosis
39#54#gene282617136#147#diseaseC0019196 23323000-1#39#54#gene282617 23323000-1#136#147#diseaseC0019196 associated_with interleukin-28B,hepatitis C
39#54#gene282617102#118#diseaseC0239946 23323000-1#39#54#gene282617 23323000-1#102#118#diseaseC0239946 associated_with interleukin-28B,hepatic fibrosis
39#54#gene282617136#147#diseaseC0019196 23323000-1#39#54#gene282617 23323000-1#136#147#diseaseC0019196 associated_with interleukin-28B,hepatitis C
56#61#gene282617102#118#diseaseC0239946 23323000-1#56#61#gene282617 23323000-1#102#118#diseaseC0239946 associated_with IL28B,hepatic fibrosis
56#61#gene282617136#147#diseaseC0019196 23323000-1#56#61#gene282617 23323000-1#136#147#diseaseC0019196 associated_with IL28B,hepatitis C
56#61#gene282617102#118#diseaseC0239946 23323000-1#56#61#gene282617 23323000-1#102#118#diseaseC0239946 associated_with IL28B,hepatic fibrosis
56#61#gene282617136#147#diseaseC0019196 23323000-1#56#61#gene282617 23323000-1#136#147#diseaseC0019196 associated_with IL28B,hepatitis C